US2007197662A1PendingUtilityA1

Amine compounds and inhibiting neurotransmitter reuptake

Assignee: RICHELSON ELLIOTTPriority: Jul 17, 2001Filed: Mar 30, 2007Published: Aug 23, 2007

Est. expiryJul 17, 2021(expired)· nominal 20-yr term from priority

Inventors:Elliott Richelson Paul Carlier

A61K 31/137C07C 215/30C07C 215/28A61K 45/06A61P 25/00A61K 31/138

PatentIndex Score

Cited by

References

Claims

Abstract

The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake.

Claims

exact text as granted — not AI-modified

1 . A composition comprising N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine.  
     
     
         2 . The composition of  claim 1 , wherein said N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine comprises (2R, 3R)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine or (2S, 3S)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine.  
     
     
         3 . The composition of  claim 1 , wherein said N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine comprises (2R, 38)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine or (2S, 3R)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine.  
     
     
         4 . The composition of  claim 1 , wherein said N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine comprises: 
 a) two compounds selected from the group consisting of (2R, 3R)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine, (2S, 38)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine, (2R, 3S)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine, and (2S, 3R)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine; or    b) three compounds selected from the group consisting of (2R, 3R)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine, (2S, 3S)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine, (2R, 3S)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine, and (2S, 3R)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine; or    c) (2R, 3R)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine, (2S, 3S)-N N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine, (2R, 3S)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine, and (2S, 3R)-N,N-dimethyl-3-hydroxy-4-methyl-2-(2′-naphthyl)pentylamine.    
     
     
         5 . The composition of  claim 1 , wherein said composition comprises a pharmaceutically acceptable carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.